IBDEI0YA ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16925,1,5,0)
 ;;=5^Hx of TB
 ;;^UTILITY(U,$J,358.3,16925,2)
 ;;=Hx of TB^303393
 ;;^UTILITY(U,$J,358.3,16926,0)
 ;;=V13.01^^92^943^36
 ;;^UTILITY(U,$J,358.3,16926,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16926,1,4,0)
 ;;=4^V13.01
 ;;^UTILITY(U,$J,358.3,16926,1,5,0)
 ;;=5^Hx of Kidney Stones
 ;;^UTILITY(U,$J,358.3,16926,2)
 ;;=Hx of Kidney Stones^303403
 ;;^UTILITY(U,$J,358.3,16927,0)
 ;;=V12.51^^92^943^59
 ;;^UTILITY(U,$J,358.3,16927,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16927,1,4,0)
 ;;=4^V12.51
 ;;^UTILITY(U,$J,358.3,16927,1,5,0)
 ;;=5^Hx of Venous Thrombosis And Embolism
 ;;^UTILITY(U,$J,358.3,16927,2)
 ;;=^303397
 ;;^UTILITY(U,$J,358.3,16928,0)
 ;;=V17.89^^92^943^18
 ;;^UTILITY(U,$J,358.3,16928,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16928,1,4,0)
 ;;=4^V17.89
 ;;^UTILITY(U,$J,358.3,16928,1,5,0)
 ;;=5^Family h/o Musculosk Disease
 ;;^UTILITY(U,$J,358.3,16928,2)
 ;;=^332861
 ;;^UTILITY(U,$J,358.3,16929,0)
 ;;=V12.54^^92^943^56
 ;;^UTILITY(U,$J,358.3,16929,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16929,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,16929,1,5,0)
 ;;=5^Hx of TIA
 ;;^UTILITY(U,$J,358.3,16929,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,16930,0)
 ;;=V12.54^^92^943^52
 ;;^UTILITY(U,$J,358.3,16930,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16930,1,4,0)
 ;;=4^V12.54
 ;;^UTILITY(U,$J,358.3,16930,1,5,0)
 ;;=5^Hx of Stroke w/o Residual
 ;;^UTILITY(U,$J,358.3,16930,2)
 ;;=^335309
 ;;^UTILITY(U,$J,358.3,16931,0)
 ;;=V15.88^^92^943^33
 ;;^UTILITY(U,$J,358.3,16931,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16931,1,4,0)
 ;;=4^V15.88
 ;;^UTILITY(U,$J,358.3,16931,1,5,0)
 ;;=5^Hx of Fall(s)
 ;;^UTILITY(U,$J,358.3,16931,2)
 ;;=^332859
 ;;^UTILITY(U,$J,358.3,16932,0)
 ;;=V13.59^^92^943^42
 ;;^UTILITY(U,$J,358.3,16932,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16932,1,4,0)
 ;;=4^V13.59
 ;;^UTILITY(U,$J,358.3,16932,1,5,0)
 ;;=5^Hx of Musculosk Disease
 ;;^UTILITY(U,$J,358.3,16932,2)
 ;;=^295268
 ;;^UTILITY(U,$J,358.3,16933,0)
 ;;=V15.52^^92^943^55
 ;;^UTILITY(U,$J,358.3,16933,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16933,1,4,0)
 ;;=4^V15.52
 ;;^UTILITY(U,$J,358.3,16933,1,5,0)
 ;;=5^Hx of TBI
 ;;^UTILITY(U,$J,358.3,16933,2)
 ;;=^338495
 ;;^UTILITY(U,$J,358.3,16934,0)
 ;;=V12.04^^92^943^38
 ;;^UTILITY(U,$J,358.3,16934,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16934,1,4,0)
 ;;=4^V12.04
 ;;^UTILITY(U,$J,358.3,16934,1,5,0)
 ;;=5^Hx of MRSA Infection
 ;;^UTILITY(U,$J,358.3,16934,2)
 ;;=^336780
 ;;^UTILITY(U,$J,358.3,16935,0)
 ;;=V13.51^^92^943^23
 ;;^UTILITY(U,$J,358.3,16935,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16935,1,4,0)
 ;;=4^V13.51
 ;;^UTILITY(U,$J,358.3,16935,1,5,0)
 ;;=5^Hs of Pathological Fx
 ;;^UTILITY(U,$J,358.3,16935,2)
 ;;=^336781
 ;;^UTILITY(U,$J,358.3,16936,0)
 ;;=V15.51^^92^943^58
 ;;^UTILITY(U,$J,358.3,16936,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16936,1,4,0)
 ;;=4^V15.51
 ;;^UTILITY(U,$J,358.3,16936,1,5,0)
 ;;=5^Hx of Traumatic Fx
 ;;^UTILITY(U,$J,358.3,16936,2)
 ;;=^336786
 ;;^UTILITY(U,$J,358.3,16937,0)
 ;;=V62.22^^92^943^49
 ;;^UTILITY(U,$J,358.3,16937,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16937,1,4,0)
 ;;=4^V62.22
 ;;^UTILITY(U,$J,358.3,16937,1,5,0)
 ;;=5^Hx of Return from Military Deployment
 ;;^UTILITY(U,$J,358.3,16937,2)
 ;;=^336807
 ;;^UTILITY(U,$J,358.3,16938,0)
 ;;=919.1^^92^944^1
 ;;^UTILITY(U,$J,358.3,16938,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,16938,1,4,0)
 ;;=4^919.1
 ;;^UTILITY(U,$J,358.3,16938,1,5,0)
 ;;=5^Abrasion, Infected
 ;;^UTILITY(U,$J,358.3,16938,2)
 ;;=^275358
 ;;^UTILITY(U,$J,358.3,16939,0)
 ;;=919.0^^92^944^2
